Article Versions Notes

Dumez H, Gallardo E, Culine S, Galceran JC, Schöffski P, Droz JP, Extremera S, Szyldergemajn S, Fléchon A. Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium. Marine Drugs. 2009; 7(3):451-463. https://doi.org/10.3390/md7030451

Dumez, Herlinde, Enrique Gallardo, Stephane Culine, Joan Carles Galceran, Patrick Schöffski, Jean P. Droz, Sonia Extremera, Sergio Szyldergemajn, and Aude Fléchon. 2009. "Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium" Marine Drugs 7, no. 3: 451-463. https://doi.org/10.3390/md7030451

Dumez, H., Gallardo, E., Culine, S., Galceran, J. C., Schöffski, P., Droz, J. P., Extremera, S., Szyldergemajn, S., & Fléchon, A. (2009). Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium. Marine Drugs, 7(3), 451-463. https://doi.org/10.3390/md7030451